Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Molecular diagnostics firm Vermillion has presented data from several studies that demonstrated the benefits of the company's ovarian cancer protein biomarker panel.
Subscribe to our email newsletter
The data suggests that the use of company’s biomarkers could help better identify women with ovarian cancer, as well as improve the detection of early-stage disease.
A clinical study examining company’s marker panel for ovarian cancer provided independent validation that it can distinguish malignant tumors from benign pelvic masses. Results of the study demonstrated that the biomarker panel could more than double the number of ovarian cancer cases referred to a gynecologic oncologist, thereby improving survival rates and reducing the number of surgeries performed.
The ovarian cancer detection study showed that company’s panel of biomarkers in combination with CA-125 could more accurately identify early-stage ovarian cancer than could CA-125 alone. CA-125 is the only tumor marker for ovarian cancer currently available on the market, however, it is not cleared for early-stage disease detection. When examining early stage disease, the combination of the two markers correctly identified 87% of the cancers.